Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
August 2, 2019 10:59 AM 2 min read

'Developing A Vocabulary That Will Be Understood': The Havas Approach To Cannabis Marketing

by Natan Ponieman
VIVHY Logo
VIVHYVivendi SE
$2.671.52%
Overview

Earlier this month, the French multinational advertising and public relations giant Havas announced the release of its cannabis division: Havas ECS.

The company, which is majority-owned by Vivendi SA (OTC:VIVEF) (OTC:VIVHY), announced it would open offices in New York and New Jersey and start operations immediately.

Benzinga spoke with Rob Dhoble, who heads the agency’s new cannabis venture.

Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!

Laying The Groundwork For Cannabis Communications

“Our mission is to advance understanding of the endocannabinoid science,” Dhoble told Benzinga in a phone interview. 

This motto might sound like it belongs to an NGO rather than a for-profit company. But it's the strategic long-term approach to cannabis communications that's being taken by Havas. 

“Only 13% of medical schools teach anything about the endocannabinoid system. The average patient feels they know more than the doctor when in fact, the doctor knows more about the body. Think of us as a communications and branding company for the vocabulary that builds bridges between clinicians, pharmacists, patients and mothers," the exec said. 

From a mass communications perspective, major players in cannabis are still largely uninformed, including physicians and consumers. 

“[Cannabis] is such an important space to us, that our commitment is that before a single piece of creative is developed, before we assess the opportunities for ourselves and our clients, let’s make sure that we’re grounding the communication strategy that will result in a vocabulary that will be understood," Dhoble said. 

Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.

A Need To Educate Audiences

“I think what makes cannabis marketing difference is that almost all communications have to have some element of education,” said Rosie Mattio, founder of Mattio Communications, a cannabis-focused marketing and PR agency.

In her view, one of the biggest challenges for cannabis communication agencies is finding creative ways to advertise while at the same time educating the audience.

“Whether it be the difference between THC and CBD, or where the plant is legal, or what investors need to consider when looking at cannabis, there is always a learning curve for both consumers and journalists,” Mattio said. 

In a way, what Havas is doing through Havas ECS is laying the groundwork for wider audiences to be able to grasp basic cannabis concepts through a universal language everyone can understand. 

Picture by Unsplash and Flaticon.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
CannabisMarketsInterview
VIVHY Logo
VIVHYVivendi SE
$2.671.52%
Overview
Comments
Loading...